Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

British Journal of Haematology

Volumn 169, Issue 5, 2015, Pages 683-688

  Gunnarsson, Niklas ^a   Stenke, Leif ^b,c   Höglund, Martin ^d   Sandin, Fredrik ^e   Björkholm, Magnus ^b,c   Dreimane, Arta ^f   Lambe, Mats ^c,e   Markevärn, Berit ^g   Olsson Strömberg, Ulla ^d   Richter, Johan ^h   Wadenvik, Hans ⁱ   Wallvik, Jonas ^a   Själander, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e Regional Cancer Centre   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic myeloid leukaemia; Malignancy; Treatment

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NON MELANOMA SKIN CANCER; NOSE CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; CANCER STAGING; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; REGISTER; RISK; SWEDEN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; REGISTRIES; RISK; SWEDEN; YOUNG ADULT;

EID: 84929234796     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13346     Document Type: Article

References (19)

1. Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D.W., Larson, R.A., Lipton, J.H., Mahon, F.X., Martinelli, G., Mayer, J., Müller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, G., Saußele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.L., Goldman, J.M. & Hehlmann, R. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872-884.
2. Barlow, L., Westergren, K., Holmberg, L. & Talbäck, M. (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncologica, 48, 27-33.
3. Barreto Miranda, M., Lauseker, M., Proetel, U., Schreiber, A., Hanfstein, B., Baerlocher, G.M., Heim, D., Ehninger, G., Hossfeld, D.K., Kolb, H.-J., Krause, S.W., Nerl, C., Einsele, H., Hänel, M., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Spiekermann, K., Hofmann, W.-K., Müller, M.C., Pfirrmann, M., Hochhaus, A., Hasford, J., Hehlmann, R. & Saussele, S. (2012) Secondary malignancies in CML patients - data from the German CML study IV. Blood (ASH Annual Meeting Abstracts), 120, 3746.
4. Björkholm, M., Ohm, L., Eloranta, S., Derolf, A., Hultcrantz, M., Sjöberg, J., Andersson, T., Höglund, M., Richter, J., Landgren, O., Kristinsson, S.Y. & Dickman, P.W. (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. Journal of Clinical Oncology, 29, 2514-2520.
5. Boggs, D.R. (1976) The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia. Seminars in Oncology, 3, 289-296.
6. Breslow, N.E. & Day, N.E. (1987) Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Scientific Publications, 82, 1-406.
7. Corm, S., Roche, L., Micol, J.B., Coiteux, V., Bossard, N., Nicolini, F.E., Iwaz, J., Preudhomme, C., Roche-Lestienne, C., Facon, T. & Remontet, L. (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood, 118, 4331-4337.
8. Crist, W.M., Ragab, A.H. & Ducos, R. (1978) Lymphoblastic conversion in chronic myelogenous leukemia. Pediatrics, 61, 560-563.
9. Frederiksen, H., Farkas, D.K., Christiansen, C.F., Hasselbalch, H.C. & Sørensen, H.T. (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood, 118, 6515-6520.
10. Gambacorti-Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C.M., Morra, E., Abruzzese, E., D'Emilio, A., Stagno, F., le Coutre, P., Hurtado-Monroy, R., Santini, V., Martino, B., Pane, F., Piccin, A., Giraldo, P., Assouline, S., Durosinmi, M.A., Leeksma, O., Pogliani, E.M., Puttini, M., Jang, E., Reiffers, J., Valsecchi, M.G. & Kim, D.W. (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103, 553-561.
11. Höglund, M., Sandin, F., Hellström, K., Björeman, M., Björkholm, M., Brune, M., Dreimane, A., Ekblom, M., Lehmann, S., Ljungman, P., Malm, C., Markevärn, B., Myhr-Eriksson, K., Ohm, L., Olsson-Strömberg, U., Själander, A., Wadenvik, H., Simonsson, B., Stenke, L. & Richter, J. (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood, 122, 1284-1292.
12. Kantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M.B., Ravandi, F., Faderl, S., Kadia, T., Borthakur, G., Huang, X., Champlin, R., Talpaz, M. & Cortes, J. (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 119, 1981-1987.
13. Loriaux, M. & Deininger, M. (2004) Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leukaemia & Lymphoma, 45, 2197-2203.
14. Majhail, N.S., Brazauskas, R., Rizzo, J.D., Sobecks, R.M., Wang, Z., Horowitz, M.M., Bolwell, B., Wingard, J.R. & Socie, G. (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood, 117, 316-322.
15. Rebora, P., Czene, K., Antolini, L., Gambacorti Passerini, C., Reilly, M. & Valsecchi, M.G. (2010) Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. American Journal of Epidemiology, 172, 1028-1033.
16. Rizzo, J.D., Curtis, R.E., Socié, G., Sobocinski, K.A., Gilbert, E., Landgren, O., Travis, L.B., Travis, W.D., Flowers, M.E., Friedman, D.L., Horowitz, M.M., Wingard, J.R. & Deeg, H.J. (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood, 113, 1175-1183.
17. Verma, D., Kantarjian, H., Strom, S.S., Rios, M.B., Jabbour, E., Quintas-Cardama, A., Verstovsek, S., Ravandi, F., O'Brien, S. & Cortes, J. (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood, 118, 4353-4358.
18. Voglova, J., Muzik, J., Faber, E., Zackova, D., Klamova, H., Steinerova, K., Michalovicova, Z., Demitrovicova, L., Cmunt, E., Novakova, L., Tothova, E., Belohlavkova, P., Mayer, J. & Indrak, K. (2011) Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma, 58, 256-262.
19. Xie, Y., Davies, S.M., Xiang, Y., Robison, L.L. & Ross, J.A. (2003) Trends in leukemia incidence and survival in the United States (1973-1998). Cancer, 97, 2229-2235.